Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalData
25 Pages - GLDATA50947
$250.00

Summary

Nektar Therapeutics (Nektar) is a biopharmaceutical company. It carries out discovery and development of a pipeline of novel therapeutic drug candidates based on its PEGylation and advanced polymer conjugate technology platforms to address unmet medical needs. Nektar’s technology platformns offers a wide array of functional attributes, which optimizes and enhances the profile of wide range of molecules including many classes of drugs targeting numerous disease areas. The company’s products focuses on various therapeutic areas, including, cancer, pain, anti-infectives, anti-viral and immunology among others. Its research and development activities involve peptides, small molecule drugs, and other potential biologic drug candidates. Nektar Therapeutics is headquartered in San Francisco, California, the US.

Nektar Therapeutics (NKTR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

'

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Nektar Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Nektar Therapeutics Completes Public Offering Of Shares For US$124.6 Million 11
Nektar Therapeutics Completes Underwritten Public Offering Of Its Common Stock For US$225 Million 13
Debt Offering 15
Nektar Therapeutics Raises USD250 Million in Private Placement of 7.75% Notes Due 2020 15
Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For US$125 Million 17
Asset Transactions 19
RPI Finance Trust Acquires Royalty of Cimzia and Mircera from Nektar Therapeutics for USD124 Million 19
Nektar Therapeutics - Key Competitors 21
Key Employees 22
Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Nektar Therapeutics, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Nektar Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Nektar Therapeutics, Deals By Therapy Area, 2010 to YTD 2016 8
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Nektar Therapeutics Completes Public Offering Of Shares For US$124.6 Million 11
Nektar Therapeutics Completes Underwritten Public Offering Of Its Common Stock For US$225 Million 13
Nektar Therapeutics Raises USD250 Million in Private Placement of 7.75% Notes Due 2020 15
Nektar Therapeutics Completes Private Placement Of Senior Secured Notes Due 2017 For US$125 Million 17
RPI Finance Trust Acquires Royalty of Cimzia and Mircera from Nektar Therapeutics for USD124 Million 19
Nektar Therapeutics, Key Competitors 21
Nektar Therapeutics, Key Employees 22
Nektar Therapeutics, Other Locations 24
Nektar Therapeutics, Subsidiaries 24

List of Figures
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Nektar Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8

$250.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838